分次立体定向放射治疗颅内肿瘤132例分析

目的：探讨立体定向分次放射治疗颅内肿瘤１３２例临床结果。方程：利用ＧＴＣ重定位头架和Ｘ刀治疗１３２例。本组病人共治疗３～１０次,３～１０Ｇｙ／次。每次间隔１～３天。结果：１３２例病,经８～３６个月（平均１４个月）随访。其中显效３１例（２３．５％）,有效８０例（６０．０％）,无效２１例（１５．９％）,出现并发症６例（４．５％）。结论：立体定向放射治疗可治疗体积较大和位于重要解剖部位的肿瘤。它不同于一般外放疗,它的治疗次数虽少而剂量大。增加ＳＲＴ治疗颅内肿瘤具有重要意义。     

EGFR-TKI单药或联合放疗治疗非小细胞肺癌肺毒性研究进展

分子靶向药物表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI）单药为EGFR敏感突变非小细胞肺癌（non-small cell lung cancer,NSCLC）患者一线治疗方案。近年来多项研究证实,其与放疗联合治疗时具有放疗增敏作用,临床研究表明其可改善晚期NSCLC患者生存且亦有可能作为无法耐受放化疗时的替代方案。EG-FR-TKI单药治疗肺毒性发生率较低但死亡率较高,与放疗联合时肺毒性发生概率不一,本文将结合相关文献围绕EG-FR-TKI类药物单药或联合放射治疗时肺毒性发生状况做一综述,为联合治疗方案的安全性提供参考。      

An investigation report of radiotherapy centers in Beijing during the COVID-19 pandemic

Objective An investigation on the prevention and control measures taken by radiotherapy centers of various hospitals in Beijing during the COVID-19 pandemic was conducted. The experience was summarized to provide reference for further work. Methods Electronic questionnaires were distributed to each radiotherapy center through members of the radiation oncology therapeutics branch of Beijing medical association and members of Society of Radiotherapy Specialists (Technicians) of Beijing Medical Doctors Association. Statistical analysis was performed based on the feedback results of electronic questionnaires. Results All forty radiotherapy centers in Beijing returned the questionnaires by the end of April 10, 2020. Except for the suspension of treatment in one center due to COVID-19 pandemic, all radiotherapy centers have taken corresponding prevention and control measures and continued to carry out radiotherapy. No COVID-19 infection of patients or medical staffs occurred during this pandemic. Conclusions During the COVID-19 pandemic, all radiotherapy centers attach great importance to optimizing the clinical process and adopt reasonable prevention and control measures. On the basis of efficient prevention and control measures, radiotherapy is delivered to fulfill the treatment demands of cancer patients.